Cellcolabs
S a biotech impact startup on a mission to use advanced cell therapies to disrupt healthcare as we know it through efficient large-scale production of mesenchymal stem cells.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $8.7m | Early VC |
| Total Funding | 000k | ||
| SEK | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 7029 % | 159 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (42307 %) | (906 %) | (540 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Cellcolabs, founded in 2021 and based in Stockholm, Sweden, specializes in the industrial GMP (Good Manufacturing Practice) production of high-quality Mesenchymal Stromal Cells (MSCs). These cells have regenerative, immunomodulatory, and anti-inflammatory properties, which could potentially cure or prevent many chronic diseases. The company aims to make MSCs available at scale to accelerate stem cell research and facilitate the development of future treatments. Cellcolabs does not provide treatments directly but sponsors or partners with clinical studies, offering updates on participation opportunities. The company serves researchers and healthcare providers in the advanced cell therapy market. Its business model revolves around the large-scale production and distribution of MSCs, generating revenue through sales to research institutions and clinical partners. Cellcolabs is committed to transforming healthcare and improving lives through advanced cell therapies.
Keywords: Mesenchymal Stromal Cells, GMP production, regenerative medicine, immunomodulatory, anti-inflammatory, chronic diseases, stem cell research, clinical studies, advanced cell therapy, healthcare transformation.